The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy
Open Access
- 25 March 2015
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 4 (4) , 504-534
Abstract
The current standard regimens for the treatment of acute myeloid leukemia (AML) are curative in less than half of patients; therefore, there is a great need for innovative new approaches to this problem. One approach is to target new treatments to the pathways that are instrumental to cell growth and survival with drugs that are less harmful to normal cells than to neoplastic cells. In this review, we focus on the MAPK family of signaling pathways and those that are known to, or potentially can, interact with MAPKs, such as PI3K/AKT/FOXO and JAK/STAT. We exemplify the recent studies in this field with specific relevance to vitamin D and its derivatives, since they have featured prominently in recent scientific literature as having anti-cancer properties. Since microRNAs also are known to be regulated by activated vitamin D, this is also briefly discussed here, as are the implications of the emerging acquisition of transcriptosome data and potentiation of the biological effects of vitamin D by other compounds. While there are ongoing clinical trials of various compounds that affect signaling pathways, more studies are needed to establish the clinical utility of vitamin D in the treatment of cancer.Keywords
Funding Information
- National Institutes of Health (R0-1 CA 22744-24 to GPS)
- Narodowe Centrum Nauki (0351/B/P01/2011/40 to EG)
- University of Wroclaw Scholarship (BPZ.506.50.2012.MS to EG)
This publication has 219 references indexed in Scilit:
- The Role of Vitamin D in Hematologic Disease and Stem Cell TransplantationNutrients, 2013
- Isoforms of p38MAPK gamma and delta contribute to differentiation of human AML cells induced by 1,25-dihydroxyvitamin D3Experimental Cell Research, 2011
- Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25‐dihydroxyvitamin D3‐induced differentiation of human acute myeloid leukemia cellsJournal of Cellular Physiology, 2010
- Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia ProteinCancer Cell, 2010
- c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin DLeukemia Research, 2009
- Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled TrialsArchives of internal medicine (1960), 2007
- Expression of human kinase suppressor of Ras 2 (hKSR-2) gene in HL60 leukemia cells is directly upregulated by 1,25-dihydroxyvitamin D3 and is required for optimal cell differentiationExperimental Cell Research, 2007
- Differentiation-inducing potency of the seco-steroid JK-1624F2-2 can be increased by combination with an antioxidant and a p38MAPK inhibitor which upregulates the JNK pathwayThe Journal of Steroid Biochemistry and Molecular Biology, 2007
- Raf‐1 signaling is required for the later stages of 1,25‐dihydroxyvitamin D3‐induced differentiation of HL60 cells but is not mediated by the MEK/ERK moduleJournal of Cellular Physiology, 2006
- Regulation of C/EBPβ isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3Experimental Cell Research, 2006